Michael Halstead - 11 Jan 2024 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role
EVP and General Counsel
Signature
/s/ Lawrence J. Hineline, Attorney-in-fact
Issuer symbol
ITCI
Transactions as of
11 Jan 2024
Net transactions value
-$2,661,648
Form type
4
Filing time
12 Jan 2024, 18:02:47 UTC
Previous filing
14 Nov 2023
Next filing
05 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITCI Common Stock Options Exercise $587,044 +46,115 $12.73* 46,115 11 Jan 2024 Direct
transaction ITCI Common Stock Options Exercise $93,007 +3,885 +8.4% $23.94 50,000 11 Jan 2024 Direct
transaction ITCI Common Stock Sale $1,203,792 -18,154 -36% $66.31 31,846 11 Jan 2024 Direct F1, F2
transaction ITCI Common Stock Sale $2,037,156 -30,360 -95% $67.10 1,486 11 Jan 2024 Direct F1, F3
transaction ITCI Common Stock Sale $100,751 -1,486 -100% $67.80 0 11 Jan 2024 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITCI Stock Option (right to buy) Options Exercise $0 -46,115 -100% $0.000000* 0 11 Jan 2024 Common Stock 46,115 $12.73 Direct F5
transaction ITCI Stock Option (right to buy) Options Exercise $0 -3,885 -15% $0.000000 22,869 11 Jan 2024 Common Stock 3,885 $23.94 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan originally adopted by the reporting person on March 15, 2023 and amended on May 8, 2023 and August 11, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.72 to $66.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.72 to $67.7094, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.745 to $67.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 All shares underlying this option have vested.